跳至主要内容
临床试验/NCT05370287
NCT05370287招募中不适用

Adaptive Optics Retinal Imaging

Food and Drug Administration (FDA)2 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2018年1月22日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
150
试验地点
2
主要终点
Change in Retinal blood flow (RBF) with oxygen inhalation

研究概览

简要总结

The objective of the study is to collect and assess adaptive optics (AO) retinal images from human subjects in support of projects to demonstrate, advance, and enhance clinical use of AO technology.

详细描述

Objective

The objective of the study is to collect and assess adaptive optics (AO) retinal images from human subjects in support of projects to demonstrate, advance, and enhance clinical use of AO technology.

Study Population: One hundred (100) healthy volunteers without eye disease and fifty (50) subjects with primary open angle glaucoma (POAG) will be enrolled.

Design: This is an interventional study protocol where participants will be imaged with investigational multimodal AO retinal imaging systems that include optical coherence tomography (OCT) and scanning laser ophthalmoscopy (SLO) channels. High resolution OCT and SLO videos will be collected while the instruments automatically detect and correct for image distortion caused by ocular aberrations. In general, videos of different retinal structures will be acquired from several retinal locations using various imaging modes.

Outcome Measures: The primary outcomes for this protocol are qualitative and quantitative assessment of the AO images and investigation of the cellular morphological and physiological changes due to glaucoma.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
None

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Are 21 years of age or older.
  • Have the ability to cooperate with instructions during adaptive optics imaging (similar to instructions given during a clinical eye exam).
  • Have the ability to understand and sign an informed consent.
  • Have been diagnosed with POAG (cohort 2).

排除标准

  • Are under 21 years of age.
  • Have a condition which prevents adequate images from being obtained (e.g. unstable fixation or media opacity).
  • Have visual correction outside of the range +4 diopters (D) to -8 D.
  • Have a history of adverse reaction to mydriatic drops.
  • Have a predisposition to (i.e., narrow iridocorneal angle) or any history of acute angle closure glaucoma (AACG).
  • Do not meet the criteria for POAG as defined by the American Academy of Ophthalmology Practice Patterns (cohort 2)
  • Have any health conditions that would contraindicate oxygen supplementation, including chronic obstructive pulmonary disease (COPD), emphysema, asthma, or any other obstructive or restrictive lung disease (RBF experiment participants only).
  • Have a dependency on oxygen support or a baseline oxygen saturation <95% (RBF experiment participants only).
  • Have tested positive for COVID-19 at initial enrollment or have acute or chronic photophobia as a result of contraction.
  • Are working under the direct supervision of Dr. Hammer.

研究组 & 干预措施

Healthy control with oxygen

Experimental

Age-matched healthy control cohort will undergo the same AO imaging procedures as glaucoma cohort. A subset of subjects will undergo the same oxygen challenge intervention as the glaucoma cohort.

干预措施: oxygen inhalation (Other)

Glaucoma with oxygen

Experimental

Primary open angle glaucoma subjects as well as pre-perimetric glaucoma suspects will be classified by clinical exam by an experienced glaucoma specialist according to the American Academy of Ophthalmology Practice Patterns. Glaucoma subjects and suspects will undergo adaptive optics (AO) imaging of several macular locations. A subset of subjects will undergo oxygen challenge intervention, which involves breathing 100% oxygen through a mask during AO imaging at pre-determined retinal vessel locations.

干预措施: Adaptive optics imaging (Device)

Healthy control with oxygen

Experimental

Age-matched healthy control cohort will undergo the same AO imaging procedures as glaucoma cohort. A subset of subjects will undergo the same oxygen challenge intervention as the glaucoma cohort.

干预措施: Adaptive optics imaging (Device)

Healthy control with stimulation

Experimental

Healthy control subjects will undergo AO imaging at several macular locations while flashes of visible light stimulus are delivered.

干预措施: Adaptive optics imaging (Device)

Glaucoma

Experimental

Glaucoma subjects and suspects will undergo AO imaging at several macular locations without intervention.

干预措施: Adaptive optics imaging (Device)

Healthy control

Experimental

Healthy control subjects will undergo AO imaging at several macular locations without intervention

干预措施: Adaptive optics imaging (Device)

Glaucoma with oxygen

Experimental

Primary open angle glaucoma subjects as well as pre-perimetric glaucoma suspects will be classified by clinical exam by an experienced glaucoma specialist according to the American Academy of Ophthalmology Practice Patterns. Glaucoma subjects and suspects will undergo adaptive optics (AO) imaging of several macular locations. A subset of subjects will undergo oxygen challenge intervention, which involves breathing 100% oxygen through a mask during AO imaging at pre-determined retinal vessel locations.

干预措施: oxygen inhalation (Other)

结局指标

主要结局

Change in Retinal blood flow (RBF) with oxygen inhalation

时间窗: RBF will be measured in all subjects twice during a single AO imaging session - once before and once during pure oxygen inhalation. Subjects will be imaged only once; there is no longitudinal component to this outcome measure.

RBF \[uL/min\] will be measured from ensemble RBC velocity \[mm/s\] measurements from line-scan AOSLO videos and vessel diameter \[mm\] measurements from average AO-OCT volumes.

Retinal ganglion cell (RGC) density

时间窗: RGC density will be calculated once at the AO imaging session in which RGCs are the target. For the reproducibility/longitudinal study portion, RGC density will be quantified three times over 1.5 years (visits separated by 6 months).

RGC density will be calculated at specific retinal eccentricities from cells counted in average AO-OCT volumes.

RGC soma diameter

时间窗: RGC diameter will be calculated once at the AO imaging session in which RGCs are the target. For the reproducibility/longitudinal portion of the study, RGC soma diameter will be quantified three times over 1.5 years (visits separated by 6 months).

RGC soma diameter will be calculated at specific retinal eccentricities from cells segmented in average AO-OCT volumes.

Retinal pigment epithelium (RPE) cell organelle motility

时间窗: RPE organelle motility will be calculated once at the AO imaging session in which RPE cells are the target. For the reproducibility portion of the study, RPE organelle motility will be quantified three times over six weeks (visits separated by 2 weeks).

RPE cell organelle motility will be calculated from the decorrelation time constant for cells segmented from a sequence of AO-OCT volumes.

Photoreceptor (PR) cell function

时间窗: PR function will be calculated once at the AO imaging session in which photoreceptors are stimulated. For the reproducibility portion of the study, PR function will be quantified three times over six weeks (visits separated by 2 weeks).

Photoreceptor cell (cone) function will be measured from phase changes between inner segment - outer segment junction and cone outer segment tip signals in a sequence of AO-OCT volumes collected during visible light stimulation.

次要结局

未报告次要终点

研究者

发起方
Food and Drug Administration (FDA)
申办方类型
Fed
责任方
Principal Investigator
主要研究者

Daniel X. Hammer

Deputy Director, Division of Biomedical Physics

Food and Drug Administration (FDA)

研究点 (2)

Loading locations...

相似试验